All In Biotech

Drug Trial Radar · NCT05368103

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Apr 27, 2022

Primary completion

Aug 7, 2023

Study completion Jan 26, 2024

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.

Conditions

  • Alopecia Areata

Interventions

  • DaxdilimabBiological

    Daxdilimab will be administered subcutaneously as two injections for each dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in SALT Score at Week 24Time frame: Baseline to Week 24

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • First OC Dermatology Research, Inc.

    Fountain Valley, California

  • ForCare Clinical Research

    Tampa, Florida

  • DS Research

    Louisville, Kentucky

  • Progressive Clinical Research, P.A.

    San Antonio, Texas

  • Dermatology Specialists of Spokane

    Spokane, Washington

  • Centre de Recherche Saint-Louis (Quebec)

    Québec, Canada

  • Enverus Medical Research

    Surrey, British Columbia, Canada

  • Dr Dusan Sajic Medicine Professional Corporation

    Guelph, Ontario, Canada

  • Lynderm Research Inc.

    Markham, Ontario, Canada

  • The Centre for Clinical Trials

    Oakville, Ontario, Canada

  • SKiN Centre for Dermatology

    Peterborough, Ontario, Canada

  • Innovaderm Research

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.